Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 5/20 | 0.31 |
| ▸ | PRKCA | P17252 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11413906 | 0.87 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL332045 | 0.85 | ATM (0.48) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL10398160 | 0.84 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL3304908 | 0.84 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL932962 | 0.84 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL12095075 | 0.83 | ATM (0.50) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL17138286 | 0.82 | ATM (0.46) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL8672226 | 0.82 | ATM (0.46) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL64811 | 0.82 | ATM (0.46) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL3406472 | 0.82 | ATM (0.46) | ATMHCAR2MAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024406-B1 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING (US) | 2012-08-01 | — | — | EP | claimed |
| US-8124689-B2 | Silicone acrylate hybride composition and method of making same | DOW CORNING CORPORATION (US) | 2012-02-28 | — | — | US | claimed |
| US-20090196911-A1 | Silicone Acrylate Hybride Composition and Method Of Making Same | DOW SILICONES CORPORATION | 2009-08-06 | — | — | US | claimed |
| EP-1940368-A2 | TRANSDERMAL DRUG DELIVERY SYSTEM WITH ACRYLATE OR METHACRYLATE FUNCTIONAL PRESSURE SENSITIVE ADHESIVE COMPOSITION | DOW CORNING CORPORATION (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007145996-A9 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING (US) | 2008-02-14 | — | — | WO | claimed |
| WO-2007050580-A2 | TRANSDERMAL DRUG DELIVERY SYSTEM WITH ACRYLATE OR METHACRYLATE FUNCTIONAL PRESSURE SENSITIVE ADHESIVE COMPOSITION | DOW CORNING CORPORATION (US) | 2007-05-03 | — | — | WO | claimed |
| EP-4395749-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS Lohmann Therapie-Systeme AG (DE) | 2024-07-10 | — | — | EP | disclosed |
| EP-3781138-B1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF SOLIFENACIN | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4048247-B1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF FINGOLIMOD | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2024-04-03 | — | — | EP | disclosed |
| US-20230241004-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE POLYMER | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230233480-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF FINGOLIMOD | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2023-07-27 | — | — | US | disclosed |
| EP-3694497-B1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE ACRYLIC HYBRID POLYMER | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023031103-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2023-03-09 | — | — | WO | disclosed |
| US-8124689-B2 | Silicone acrylate hybride composition and method of making same | DOW CORNING CORPORATION (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090196911-A1 | Silicone Acrylate Hybride Composition and Method Of Making Same | DOW SILICONES CORPORATION | 2009-08-06 | — | — | US | disclosed |
| EP-2024406-A2 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING CORPORATION (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1940368-A2 | TRANSDERMAL DRUG DELIVERY SYSTEM WITH ACRYLATE OR METHACRYLATE FUNCTIONAL PRESSURE SENSITIVE ADHESIVE COMPOSITION | DOW CORNING CORPORATION (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007145996-A9 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007145996-A2 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007050580-A2 | TRANSDERMAL DRUG DELIVERY SYSTEM WITH ACRYLATE OR METHACRYLATE FUNCTIONAL PRESSURE SENSITIVE ADHESIVE COMPOSITION | DOW CORNING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090196911-A1 | Silicone Acrylate Hybride Composition and Method Of Making Same | MMS19, CAD, ACR | ATM 331/4885HCAR2 1115/4885MAPT 2025/4885 |
| US-20230241004-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE POLYMER | PDE2A, PDE3A, PDE3B | ATM 2261/4885HCAR2 1840/4885MAPT 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.